Rose McNulty

The approval marks the second for a generic in this class of medications indicated to improve glycemic control in patients with type 2 diabetes as a complement to diet and exercise.

In the final part of our interview, Ticiana Leal, MD, Winship Cancer Institute, looks to the future of perioperative care in the non–small cell lung cancer (NSCLC) arena and the importance of risk stratifying patients.

Ticiana Leal, MD, Winship Cancer Institutes, explains the importance of biomarker testing and multidisciplinary conversations while caring for patients with early-stage non–small cell lung cancer (NSCLC).

While previous trials have led to questions surrounding the potential benefits of valve interventions in mitral or tricuspid regurgitation, a pair of trials presented recently demonstrate their potential, Javed Butler, MD, MPH, MBA, president of the Baylor Scott and White Research Institute, said.

HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death.

In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.

Daratumumab plus VRd and frontline daratumumab plus VTd produced deep, durable responses in patients with transplant-eligible multiple myeloma in updates to the PERSEUS and CASSIOPEIA trials, respectively.

JT Lew, PharmD, MBA, managed care pharmacist at MultiCare Health System, spoke to the impacts of processes such as prior authorization and step therapy requirements in the realm of multiple sclerosis (MS).

Bimekizumab-bkzx (Bimzelx) is now FDA approved for 4 chronic immune-mediated inflammatory diseases: psoriatic arthritis, nonradiographic axial spondyloarthritis (axSpA), ankylosing spondylitis, and moderate to severe plaque psoriasis.

New findings add to the understanding of the patient experience in axial spondyloarthritis (axSpA), which can help inform patient-centered clinical care.

Cases of atrial arrhythmia in patients with Duchenne muscular dystrophy (DMD) are common but lack a standard solution, and more long-term data on the management of arrhythmias in DMD are needed.

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

The first overall survival analysis of the KEYNOTE-522 trial showed positive outcomes with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab monotherapy vs neoadjuvant chemotherapy alone in high-risk early-stage triple-negative breast cancer (TNBC).

Nicolas Girard, MD, head of the Curie-Montsouris Thorax Institute, discusses patient-reported outcomes (PROs) from the phase 2 LUMINOSITY trial of telisotuzumab vedotin (Teliso-V) in non–small cell lung cancer (NSCLC).

Mirvetuximab soravtansine showed high evidence of efficacy in heavily pretreated FRα-positive, platinum-sensitive ovarian cancer, which is a challenging patient population to treat, Angeles Alvarez Secord, MD, MHSc, gynecologic oncologist at Duke Health, said.

Sheela Rao, MBBS, FRCP, MD, consultant medical oncologist at the Royal Marsden Hospital, discussed the findings of the POD1UM-303/InterAACT2 trial of retifanlimab plus chemotherapy for squamous cell carcinoma of the anal canal (SCAC).

Jonathan Riess, MD, MS, director of thoracic medicine at UC Davis Health, gave insight into the rationale and efficacy data for combining cancer vaccine IO102-IO103 with pembrolizumab in advanced squamous cell carcinoma of the head and neck.

Deepened, persistent responses were seen in the long term among patients with advanced melanoma treated with fianlimab and cemiplimab, Meredith McKean, MD, MPH, director of melanoma and skin cancer research for Sarah Cannon Research Institute, explained.

New prevalence estimates of atrial fibrillation found that approximately 10.5 million US adults, or 5% of the population, have the condition.

The rate of uninsurance in 2023 was 8.0%, a statistically insignificant change from the 7.9% uninsured rate in 2022.

An electronic version of the Symbol-Digit Modalities Test could enable people with multiple sclerosis (MS) to perform frequent remote cognitive assessments independently.

Dax Kurbegov, MD, senior vice president of Sarah Cannon Cancer Network, discussed divides between payers, health systems, and oncology care providers, as well as the impacts these divides can have on patients.

The findings may help inform policy changes at the federal level aiming to address unfair and deceptive pharmacy benefit manager (PBM) practices.

Measurements on a standard phantom and a clinical data set of patients with Duchenne muscular dystrophy (DMD) were used to validate a novel robust reference frequency method approach, which outperformed typical imaging strategies.

Ticiana Leal, MD, associate professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses the latest advances in perioperative non–small cell lung cancer (NSCLC) treatment.

Neil Goldfarb, president and chief executive officer of the Greater Philadelphia Business Coalition on Health (GPBCH), previews the variety of themes and sessions at the upcoming GPBCH Annual Wellness Summit taking place September 10, 2024.

The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS).

Jason Romancik, MD, a board-certified hematologist at Emory Winship Cancer Institute, discusses the current treatment landscape in aggressive lymphoma and drivers of high care costs.